<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurol Genet</journal-id>
<journal-id journal-id-type="hwp">nng</journal-id>
<journal-id journal-id-type="publisher-id">NNG</journal-id>
<journal-title-group>
<journal-title>Neurology: Genetics</journal-title>
</journal-title-group>
<issn pub-type="epub">2376-7839</issn>
<publisher>
<publisher-name>Wolters Kluwer</publisher-name>
<publisher-loc>Baltimore</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29264397</article-id>
<article-id pub-id-type="pmc">5733250</article-id>
<article-id pub-id-type="publisher-id">NG2017005967</article-id>
<article-id pub-id-type="doi">10.1212/NXG.0000000000000206</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>60</subject>
<subject>229</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical features and outcome of 6 new patients carrying de novo <italic>KCNB1</italic> gene mutations</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Marini</surname>
<given-names>Carla</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Associate Editor of Epileptic Disorder</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>Speaker honoraria at VII CONGRESSO NAZIONALE SIMMESN - Firenze 16-18 dicembre 2015, from SOBI, Swedish Orphan Biovitrum</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Member of the editorial board of Epilepsia (2007-2012) Associate Editor of Epileptic Disorder (2014-2016)</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>Italian Minister of Health, Research Program Section, (RF- 2009-1525669). Title of the project: Clinical and genetic study of early onset epilepsies of unknown aetiology Duration: 2011-2013</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Research grant from CARIPLO foundation, Milan, Italy (01/05/2014 to 01/02/2016): Clinical characterization of PCDH19 mutations</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Romoli</surname>
<given-names>Michele</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parrini</surname>
<given-names>Elena</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Costa</surname>
<given-names>Cinzia</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mei</surname>
<given-names>Davide</given-names>
</name>
<degrees>MSc</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>1) BioMarin Pharmaceutical, Funding for travel &amp; Honoraria for speaking engagements</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>(1) Epilepsia, Editorial Board, 2011-2017</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mari</surname>
<given-names>Francesco</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parmeggiani</surname>
<given-names>Lucio</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Procopio</surname>
<given-names>Elena</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Metitieri</surname>
<given-names>Tiziana</given-names>
</name>
<degrees>Psyd, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cellini</surname>
<given-names>Elena</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Virdò</surname>
<given-names>Simona</given-names>
</name>
<degrees>MSc</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>De Vita</surname>
<given-names>Dalila</given-names>
</name>
<degrees>BSc</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gentile</surname>
<given-names>Mattia</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Prontera</surname>
<given-names>Paolo</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Calabresi</surname>
<given-names>Paolo</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Guerrini</surname>
<given-names>Renzo</given-names>
</name>
<degrees>MD, FRCP</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Honoraria for Advisory Board activities and travel related expenses for: (1) Eisai Inc, (2) Novartis, (3) Zogenix, (4) Biomarin.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>(1) EISAI: funding for travel. (2) Novartis funding for travel; (3) UCB: Funding for travel. (3) Biomarin funding for travel.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>(1) Epilepsia: Associate Editor 2006-2013, (2) Progress in Epileptic Disorders, International Advisory Board, 2007- (3) Neuropediatrics, Editorial Board, 2001-2009 (4) Journal of Child Neurology, Editorial Board, 1995-2010, (5) Seizure, Editorial Board 2005-, (6) BMC Medical Genetics,Editorial Board, 2006-, (7) Topics in Epilepsy, Editorial Board, 2009- (8) Journal of Pediatric Epilepsy, Editorial Board, 2011- (9) Epileptic Disorders,Editorial Board, 1999-2012 (10) European Neurological Journal, Editorial Board, 2010- (11) Neurology, Editorial Board, 2013- (12) Journal of Embryology &amp; Developmental Biology, 2016-</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>(1) Epilepsy and Movements disorders, Cambridge University Press, 2002, (2) Aicardi's Epilepsy in Children, Lippincott Williams &amp; Wilkins, 2004, (3) Progress in Epileptic Spasms and West Syndrome, John Libbey Eurotext, 2007, (4) Epilepsy and Migraine, John Libbey Eurotext, 2009, (5) The Causes of Epilepsy, Cambridge University Press, 2011. (6) Dravet syndrome, John Libbey Eurotext, 2011. (7) Epilepsy and epileptic seizures, Oxford University Press, 2012</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) EU contract number LSH-CT-2006-2011 037315 (EPICURE) FP6 - LIFESCIHEALTH. Subproject Coordinator (2) Tuscany Region. Research Department. Drug treatment and neuroprotection in hypoxic-ischemic brain injury and neonatal? infantile seizures. 2010-2013. Project Coordinator. (3) EC PROGRAM Rare disease: use of clinical trial simulation for the choice and optimization of study Design: Era-Net. 2011 ? 2014. Unit Coordinator. (4) EC. Genetics of cortical gyral dysgenesis and pathophysiology of tubulin-related malformations of cortical development. EU PROGRAM: E-RARE2. 2012-2014. Unit Coordinator. (5) EC FP7, 2013-2018. DESIRE: Development and Epilepsy - Strategies for Innovative Research to improve diagnosis, prevention and treatment in children with difficult to treat Epilepsy. Grant Agreement 6602531; Project Coordinator, 2013-2018. Italian Ministry of Health and Tuscany Region: An integrated approach to unravel the genetic causes and molecular pathogenesis of epileptogenic focal cortical dysplasia. RF-2013-02355240. 2016-2019. Project Coordinator.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Pisa Foundation. Grant Title: Development of technology for the diagnostic characterisation and post-chemotherapy- radiotherapy monitoring of paediatric brain tumours using ultra high field MRI. 2013-2016. Project Coordinator.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>From the Pediatric Neurology Unit (C.M., E.P., D.M., F.M., T.M., E.C., S.V., D.D.V., R.G.), Neurogenetics and Neurobiology Laboratories, Neuroscience Department, A. Meyer Pediatric Hospital, University of Florence; Neurology Unit (M.R., C.C., P.C.), Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia; Child Neurology Service (L.P.), Hospital of Bolzano; Metabolic Unit (E.P.), A. Meyer Pediatric Hospital, Florence; Medical Genetics Unit (M.G.), Azienda Sanitaria Locale Bari; Neonatology Unit and Prenatal Diagnosis (P.P.), Medical Genetic Unit, Ospedale S. Maria della Misericordia, Perugia; Department of Experimental Neurosciences (P.C.), “Istituto di Ricovero e Cura a Carattere Scientifico,” IRCCS Santa Lucia Foundation, Rome; and IRCCS Stella Maris Foundation (R.G.), Calambrone, Pisa, Italy.</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence to Dr. Guerrini: <email>renzo.guerrini@meyer.it</email></corresp>
<fn fn-type="financial-disclosure">
<p>Funding information and disclosures are provided at the end of the article. Go to <ext-link ext-link-type="uri" xlink:href="http://ng.neurology.org/lookup/doi/10.1212/NXG.0000000000000206">Neurology.org/ng</ext-link> for full disclosure forms. The Article Processing Charge was funded by the University of Florence.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>11</day>
<month>12</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>3</volume>
<issue>6</issue>
<elocation-id>e206</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>6</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>9</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p>
</license>
</permissions>
<self-uri xlink:href="NG2017005967.pdf" xlink:title="pdf"></self-uri>
<abstract>
<sec>
<title>Objective:</title>
<p>To describe electroclinical features and outcome of 6 patients harboring <italic>KCNB1</italic> mutations.</p>
</sec>
<sec>
<title>Methods:</title>
<p>Clinical, EEG, neuropsychological, and brain MRI data analysis. Targeted next-generation sequencing of a 95 epilepsy gene panel.</p>
</sec>
<sec>
<title>Results:</title>
<p>The mean age at seizure onset was 11 months. The mean follow-up of 11.3 years documented that 4 patients following an infantile phase of frequent seizures became seizure free; the mean age at seizure offset was 4.25 years. Epilepsy phenotypes comprised West syndrome in 2 patients, infantile-onset unspecified generalized epilepsy, myoclonic and photosensitive eyelid myoclonia epilepsy resembling Jeavons syndrome, Lennox-Gastaut syndrome, and focal epilepsy with prolonged occipital or clonic seizures in each and every one. Five patients had developmental delay prior to seizure onset evolving into severe intellectual disability with absent speech and autistic traits in one and stereotypic hand movements with impulse control disorder in another. The patient with Jeavons syndrome evolved into moderate intellectual disability. Mutations were de novo, 4 missense and 2 nonsense, 5 were novel, and 1 resulted from somatic mosaicism.</p>
</sec>
<sec>
<title>Conclusions:</title>
<p><italic>KCNB1</italic>-related manifestations include a spectrum of infantile-onset generalized or focal seizures whose combination leads to early infantile epileptic encephalopathy including West, Lennox-Gastaut, and Jeavons syndromes. Long-term follow-up highlights that following a stormy phase, seizures subside or cease and treatment may be eased or withdrawn. Cognitive and motor functions are almost always delayed prior to seizure onset and evolve into severe, persistent impairment. Thus, <italic>KCNB1</italic> mutations are associated with diffuse brain dysfunction combining seizures, motor, and cognitive impairment.</p>
</sec>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>OPEN-ACCESS</meta-name>
<meta-value>TRUE</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p>The <italic>KCNB1</italic> gene encodes the pore-forming and voltage-sensing β subunit of the voltage-gated potassium (K<sup>+</sup>) channel subfamily 2 (Kv2.1) that is expressed throughout the brain<sup><xref ref-type="bibr" rid="R1">1</xref><xref ref-type="bibr" rid="R2">–</xref><xref ref-type="bibr" rid="R3">3</xref></sup> and plays essential roles in regulating neuronal excitability, contributing to action potential repolarization<sup><xref ref-type="bibr" rid="R4">4</xref></sup> and dynamic modulation of neuronal activity.<sup><xref ref-type="bibr" rid="R5">5</xref><xref ref-type="bibr" rid="R6">–</xref><xref ref-type="bibr" rid="R7">7</xref></sup> De novo heterozygous missense (number = 13) and nonsense (number = 1) mutations of <italic>KCNB1</italic> have been reported in 14 patients with neurodevelopmental disorders, including epilepsy of variable severity in 13 of them.<sup><xref ref-type="bibr" rid="R8">8</xref><xref ref-type="bibr" rid="R9">–</xref><xref ref-type="bibr" rid="R15">15</xref></sup> Probands carrying <italic>KCNB1</italic> mutations resulting in severe epilepsy phenotypes have been classified as epileptic encephalopathy–early infantile 26 (OMIM: EIEE26, *600397). <xref ref-type="table" rid="T1">Table 1</xref> summarizes the clinical and genetic features of previously reported patients.</p>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Clinical and genetic summary of previously published patients</p>
</caption>
<graphic xlink:href="NG2017005967TT1"></graphic>
</table-wrap>
<p>Here, we describe the electroclinical features and long-term follow-up of 6 novel patients carrying de novo missense and nonsense <italic>KCNB1</italic> mutations and provide an overall view of the spectrum of epilepsy phenotypes associated with <italic>KCNB1</italic> mutations, ranging from Lennox-Gastaut syndrome to remitting infantile spasms and to mild generalized epilepsy with eyelid myoclonia. Our small cohort of patients also suggests that the <italic>KCNB1</italic> EIEE26 manifests infantile-onset seizures with a tendency to attenuate or resolve completely over time in some patients. Concomitant impairment of cognitive and motor functions, constant and often severe, persists over time and is at times combined with absent speech, autism spectrum disorder (ASD), and psychiatric problems. Mutations in this gene, which are not rare, confirm that genes coding for potassium channels are important genetic contributors to epilepsies and more broadly to neurodevelopmental disorders.</p>
<sec id="s1" sec-type="methods">
<title>METHODS</title>
<p>From a highly heterogenous cohort of 873 patients with pediatric epilepsies, either refractory or benign, with a supposed genetic etiology, recruited at the Meyer Children's Hospital or referred from other national or international epilepsy centers for genetic testing, we identified and studied 6 patients carrying de novo variants of the <italic>KCNB1</italic> gene (GenBank Accession Number: NM_004975.2). Three patients were examined at the Neurology unit, and 3 were referred for genetic testing to our Neurogenetic Laboratory. Collection and analysis of retrospective clinical, EEG, neuropsychological, neuroimaging data were performed using a specific format filled by the treating specialist aiming to obtain accurate and homogenous information. We classified seizure types and epilepsy/syndromes according to the International League Against Epilepsy guidelines.<sup><xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R17">17</xref></sup></p>
<sec id="s1-1">
<title>Molecular genetic testing.</title>
<p>Genomic DNA was extracted from peripheral blood leukocytes using a QIAsymphony SP robot (Qiagen, Hilden, Germany) according to the manufacturer's protocol. High-quality DNA was quantified using a QuantiFluor Fluorometer (Promega, Madison, WI). Targeted resequencing of a panel including 95 genes associated with epilepsy was performed in all 6 patients. Target enrichment and library preparation were performed using a custom-designed Nextera Rapid Capture assay (Illumina, San Diego, CA), and sequencing was performed on an Illumina MiSeq (Illumina) with a 2 × 150-bp paired-end protocol as previously described.<sup><xref ref-type="bibr" rid="R18">18</xref></sup> Variants were annotated and filtered using the ANNOVAR tool.<sup><xref ref-type="bibr" rid="R19">19</xref></sup> Variants localized in intronic regions outside the 10-bp exon-flanking boundaries and in the 5′- and 3′-UTR regions were excluded. Variants reported in the Exome Aggregation Consortium (ExAC) database (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/">exac.broadinstitute.org/</ext-link>) and/or in the 1000 Genomes Project (in the National Heart, Lung, and Blood Institute Exome Sequencing Project [ESP], ESP6500 database, <ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS)">evs.gs.washington.edu/EVS</ext-link>), in the Genome Aggregation Database (gnomAD) (<ext-link ext-link-type="uri" xlink:href="http://gnomad.broadinstitute.org/">gnomad.broadinstitute.org/</ext-link>), with a minor allele frequency &gt;0.01 (1%) were dropped out. In silico prediction of mutations' pathogenicity was obtained using the dbNSFP database (v3.3), which provides functional prediction scores on more than 20 different algorithms (<ext-link ext-link-type="uri" xlink:href="https://sites.google.com/site/jpopgen/dbNSFP">sites.google.com/site/jpopgen/dbNSFP</ext-link>). Putative causative variants were analyzed by Sanger sequencing to confirm the next-generation sequencing (NGS) results in probands and investigated in the parents to check the inheritance status. We classified variants according to the international guidelines of the American College of Medical Genetics and Genomics (ACMG) Laboratory Practice Committee Working Group.<sup><xref ref-type="bibr" rid="R20">20</xref></sup></p>
</sec>
<sec id="s1-2">
<title>Standard protocol approvals, registrations, and patient consents.</title>
<p>Written informed consent to disclose clinical information was obtained from all parents/guardians of the participants. Written informed consent for genetic testing was obtained according to the Paediatric Ethic Committee of the Tuscany Region (approval no. 2014-0000559) in the context of the DESIRE project (grant agreement no. 602531).</p>
</sec>
</sec>
<sec id="s2" sec-type="results">
<title>RESULTS</title>
<p>The 6 patients (4 females and 2 males) harboring <italic>KCNB1</italic> mutations had a mean age at the time of the study of 12 years (range 7–22 years). They represented the 0.75% (6 of 873) of a highly heterogeneous cohort of patients with potentially genetic epilepsies, studied with our target resequencing gene panel.<sup><xref ref-type="bibr" rid="R18">18</xref></sup>
<xref ref-type="table" rid="T2">Table 2</xref> summarizes the main clinical features of each <italic>KCNB1</italic> mutation–positive patient.</p>
<table-wrap id="T2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<p>Clinical and genetic summary of the 6 patients reported harboring <italic>KCNB1</italic> mutations</p>
</caption>
<graphic xlink:href="NG2017005967TT2"></graphic>
</table-wrap>
<sec id="s2-1">
<title>Epilepsy.</title>
<p>The mean age at seizure onset was 11 months (median 9, range 5–23 months). Four of the 6 patients (66.6%) following an initial phase of active epilepsy with frequent seizures became seizure free at a median age of 4.25 years; the mean duration of seizure remission at the last follow-up was 6 years (range 8 months–16 years).</p>
<p>Seizure types (<xref ref-type="table" rid="T2">table 2</xref>) included infantile spasms (patients 1 and 2), myoclonic seizures with eyelid myoclonia (<xref ref-type="table" rid="T2">table 2</xref>, patient 3), febrile seizures (FS) followed by focal seizures (patients 4 and 5), absences and nonconvulsive status epilepticus (patient 6), and afebrile tonic-clonic seizures (TCS) followed by other generalized seizure types (patients 5 and 6). For each patient, we considered age of symptom appearance and age at the time of the study and calculated a mean follow-up of 11.3 years when last seen (median 8.5 years, range 6–21 years).</p>
<p>Two patients with infantile spasms (patients 1 and 2), classified as West syndrome due to their hypsarrhythmic EEG and co-occurring developmental delay, exhibited an identical phenotype and outcome. Both patients were immediately treated with adrenocorticotropic hormone (ACTH) after the onset of spasms, with a prompt remission of spasms and EEG improvement. After 6–7 years of follow-up, both patients with “remitting infantile spasms” remain seizure free and off antiepileptic drugs (AEDs). Yet, their development was delayed and currently sets on severe impairment of cognitive and motor functions including absent speech.</p>
<p>The remaining 4 patients manifested different and heterogeneous phenotypes. Patient 3 (<xref ref-type="table" rid="T2">table 2</xref>) showed an interesting and peculiar phenotype consisting of myoclonic seizures and absences with eyelid myoclonia with persistent generalized photosensitivity. Her epilepsy started at 6 months, with bilateral myoclonic jerks, and was very active for 3 months when treatment with valproic acid (VPA) prompted a prolonged, yet temporary, resolution of symptoms. Indeed, at age 7 years, during primary school age, myoclonic seizures and absences with eyelid myoclonia with photosensitivity were observed (<xref ref-type="fig" rid="F1">figure 1A</xref>). Episodes of absences with eyelid myoclonia occurred frequently on eye closure or were autoinduced like seen in Jeavons syndrome.<sup><xref ref-type="bibr" rid="R21">21</xref></sup> Two generalized TCS during sleep were also reported around age 15 years. The patient was trialed with several AEDs, but only a combination of VPA, ethosuximide, and clonazepam was effective at age 16 years. At the time of the study, this patient was 22 years old and is still seizure free on AEDs. Patients 4 and 5 (<xref ref-type="table" rid="T2">table 2</xref>) exhibited infantile-onset multifocal and generalized seizures preceded by global developmental delay. Then, patient 4 manifested monthly seizures from age 2 to 5 years when seizures ceased, she is currently 12, still on AEDs, and seizure free. Despite 5 years of seizure freedom, her cognitive and motor functions are yet severely impaired with absent speech and autistic traits. Patient 5 has ongoing yearly seizures and severe cognitive impairment. The last patient (patient 6) exhibited the most refractory epilepsy with infantile-onset FS followed by focal seizures, frequent absences, nonconvulsive status, tonic, and TCS configuring a phenotype resembling Lennox-Gastaut syndrome. He is currently 17 and has daily atypical absences and sleep-related TCS. Concomitant with such refractory epilepsy, he manifested early developmental delay evolving into moderate to severe intellectual disability (ID) with a behavioral disorder requiring antipsychotic drugs.</p>
<fig id="F1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<title>Representative EEG findings in 3 patients</title>
<p>(A) Ictal videopolygraphic EEG recording of patient 3 (<xref ref-type="table" rid="T2">table 2</xref>), showing discharges of diffuse polyspike waves concomitant with myoclonic jerks evident on the leads recording from both deltoid muscles. (B) Ictal videopolygraphic EEG recording of patient 3 (<xref ref-type="table" rid="T2">table 2</xref>), showing generalized paroxysmal activity evoked by eye closure with concomitant eyelid myoclonia (video available as supplementary material). (C) Interictal EEG recording of patient 5, showing bifrontal single complexes of spikes and waves with left predominance. (D) Interictal sleep EEG recording of patient 4, showing very frequent paroxysmal activity over the fronto-centro-temporal regions (continuous spikes and waves during the slow-wave sleep pattern).</p>
</caption>
<graphic xlink:href="NG2017005967FF1"></graphic>
</fig>
<sec id="s2-1-1">
<title>EEG recordings.</title>
<p>All patients underwent repeated EEG recordings from seizure onset to current age. According to their epilepsy phenotype, at onset, 2 patients presented a severely abnormal EEG with hypsarrhythmia that overtime evolved into a normal EEG in 1 (patient 2) and slow background activity with rare left temporal spikes in the second patient (patient 1). Video-EEG polygraphic recordings of the patient with Jeavons syndrome (patient 3) showed, at onset and during follow-up, generalized spike- and polyspike-wave discharges with a prominent generalized photoparoxysmal response (<xref ref-type="fig" rid="F1">figure 1B</xref>). Several episodes of myoclonia and absences with eyelid myoclonia were recorded (<xref ref-type="fig" rid="F1">figure 1, A and B</xref>). Patient 4 (<xref ref-type="table" rid="T2">table 2</xref>), with infantile-onset multifocal epilepsy, consistently showed slow background with multifocal or diffuse paroxysmal activity in sleep and semiperiodic posterior fast activity runs on awakening. Some EEG recordings in this patient showed, in early childhood, a relevant increase in paroxysmal activity during sleep, resembling the continuous spike and wave during the slow-wave sleep (CSWS) EEG pattern (<xref ref-type="fig" rid="F1">figure 1C</xref>). The EEG recordings in patient 5 (<xref ref-type="table" rid="T2">table 2</xref>) exhibited slow background activity and intermittent bilateral frontocentral spike and wave discharges with left predominance (<xref ref-type="fig" rid="F1">figure 1B</xref>). EEG recordings of patient 6 showed slow background and frequent, at times almost continuous multifocal and diffuse spike and wave discharges.</p>
</sec>
<sec id="s2-1-2">
<title>Cognition and behavior.</title>
<p>Five of the 6 patients (<xref ref-type="table" rid="T2">table 2</xref>, patients 1, 2, and 4–6) had clear-cut developmental delay prior to seizure onset, involving both motor and cognitive functions. Their cognitive outcome evolved into severe impairment with absent speech and autistic traits in 1 (<xref ref-type="table" rid="T2">table 2</xref>, patient 4). In addition, one of them (<xref ref-type="table" rid="T2">table 2</xref>, patient 5) manifested stereotypic hand movements and impulse control disorder consisting of trichotillomania, and patient 6 (<xref ref-type="table" rid="T2">table 2</xref>) developed a psychiatric disorder requiring treatment with neuroleptics.</p>
<p>The girl with Jeavons syndrome instead had a delayed early development (sitting: 8 months, ambulation: 15 months; and language: 2 years) evolving, in childhood, into mild cognitive impairment with motor and verbal dyspraxia and poor coordination. Despite such a cognitive profile, she attended primary school unassisted. While during secondary school, she required a special needs teacher, and further neuropsychological testing documented moderate ID (Wechsler Intelligence Scale for Children—Revised: full-scale IQ = 45). Yet, she was able to reach secondary school graduation.</p>
<p>Five of the 6 patients acquired independent walking, with a variable degree of hypotonia, hyperlaxity, and mild ataxia in 3. One patient was using a wheelchair (patient 1).</p>
</sec>
<sec id="s2-1-3">
<title>MRI.</title>
<p>All patients underwent normal brain MRI.</p>
</sec>
</sec>
<sec id="s2-2">
<title>Genetic.</title>
<p>Heterozygous <italic>KCNB1</italic> mutations occurred de novo (<xref ref-type="table" rid="T2">table 2</xref>, <xref ref-type="fig" rid="F2">figure 2</xref>) and were classified as pathogenic according to the ACMG guidelines. Both patients 1 and 2 carried a novel de novo nonsense mutation, including the c.1109G&gt;A [p.(Trp370*)] variant that is located in the pore domain of the protein and the c.1747C&gt;T [p.(Arg583*)] variant, which falls in the C-terminal domain. Patient 3 harbored the c.916C&gt;T [p.(Arg306Cys)] missense variant, which is located in the S4 segment of the voltage-sensor domain of the protein. This variant had previously been reported in a patient with developmental delay and infantile-onset seizures.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> Patient 4 carried the novel c.586A&gt;T [p.(Ile196Phe)] missense variant, located in the S1 segment of the protein, and patient 5 carried the novel c.629C&gt;T [p.(Thr210Met)] missense variant, located in the first extracellular domain, between S1 and S2. Patient 6 carried the novel c.1045G&gt;T [p.(Val349Phe)] missense variant, located in the S5 segment of the pore; both NGS and Sanger sequencing data showed evidence of somatic mosaicism (figure e-1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXG/A1">http://links.lww.com/NXG/A1</ext-link>). None of the <italic>KCNB1</italic> variants were reported in the public available allele frequency databases (table e-1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXG/A0">http://links.lww.com/NXG/A0</ext-link>), and the tools included in the dbNSFP, comprising the MetaSVM and MetaLR ensemble scores, predicted the 4 missense variants to be damaging (table e-1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXG/A0">http://links.lww.com/NXG/A0</ext-link>).</p>
<fig id="F2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<title>Schematic representation of the Kv2.1 protein with mutation distribution</title>
<p>Structure of the human Kv2.1 channel including previously published mutations and those reported here (specified under each mutation). The protein topology was performed using the Protter online tool (29) with the Uniprot accession Q14721 (KCNB1_HUMAN).</p>
</caption>
<graphic xlink:href="NG2017005967FF2"></graphic>
</fig>
</sec>
</sec>
<sec id="s3" sec-type="discussion">
<title>DISCUSSION</title>
<p>We describe the electroclinical features and outcome of 6 patients harboring de novo heterozygous <italic>KCNB1</italic> mutations, confirming that mutations in this gene are not rare. Indeed, in our highly heterogenous cohort of pediatric epilepsies with a supposed genetic etiology, nearly 1% of patients carried mutations in this gene.</p>
<p>Genetic studies, from the “old” linkage analyses studies to the modern era of whole-exome sequencing/whole-genome sequencing techniques, have demonstrated that heterozygous mutations in several genes coding for different K<sup>+</sup> channels, including <italic>KNCQ2</italic>, <italic>KCNQ3</italic>, <italic>KCNA2</italic>, <italic>KCNA1</italic>, <italic>KCNC1</italic>, <italic>KCNH1</italic>, <italic>KCNMA1</italic>, <italic>HCN2</italic>, and <italic>KCNT1</italic>, are involved in epileptic disorders whose severity varies from benign forms to early infantile epileptic encephalopathy (EIEE).<sup><xref ref-type="bibr" rid="R22">22</xref><xref ref-type="bibr" rid="R23">–</xref><xref ref-type="bibr" rid="R32">32</xref></sup> The list of K<sup>+</sup> channel genes implicated in epilepsy includes <italic>KCNB1</italic> that was, in 2014, linked to the EIEE26.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> At present, there are 14 patients on record carrying mutations in this gene, and 13 of them exhibit epilepsy.<sup><xref ref-type="bibr" rid="R8">8</xref><xref ref-type="bibr" rid="R9">–</xref><xref ref-type="bibr" rid="R15">15</xref></sup></p>
<p>All patients, including the 6 reported here, present with early motor and cognitive delay and, thenceforth, with different types of infantile-onset seizures. Review of previously published patients shows that both focal and generalized seizures including tonic-clonic, tonic, atonic, absences, myoclonic seizures, and infantile spasms can be equally observed (<xref ref-type="fig" rid="F3">figure 3A</xref>). Epilepsy, often classified as early-onset epileptic encephalopathy, has been reported as severe and refractory to AEDs in most patients. In our small series, 2 of the 6 patients were diagnosed as West syndrome (<xref ref-type="fig" rid="F3">figure 3B</xref>). Of the remaining 4, 2 had generalized epilepsy with myoclonic seizures and eyelid myoclonia with photosensitivity, resembling Jeavons syndrome in 1 (<xref ref-type="fig" rid="F3">figure 3B</xref>). Focal epilepsy with prolonged occipital seizures or focal clonic, possibly frontal, seizures was documented only in 1, and the last, sixth patient's, had a phenotype consistent with Lennox-Gastaut syndrome (<xref ref-type="fig" rid="F3">figure 3B</xref>).</p>
<fig id="F3" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<title>Graphic representation of seizure type distribution in patients with <italic>KCNB1</italic> mutations</title>
<p>(A) Previously published patients (data from 10 of the 13 patients of previously published <italic>KCNB1</italic> mutations and epilepsy) and (B) in our series of 6 patients. AB = absences; CSWS = continuous spikes and waves during slow-wave sleep; FS = febrile seizures; MY = myoclonia; NCSE = nonconvulsive status epilepticus; TCS = tonic-clonic seizures.</p>
</caption>
<graphic xlink:href="NG2017005967FF3"></graphic>
</fig>
<p>Combining the analysis of the seizure types of all known patients harboring <italic>KCNB1</italic> mutations (including our 6 probands and the 14 previously published, for a total of 20, of whom 19 with seizures), we can observe that (1) TCS are the commonest seizure type observed in 57.8% (11/19) of patients; (2) focal seizures are the second most common type, reported in 47% (9/19); (3) infantile spasms are also a relatively common manifestation occurring in 31.5% (6/19); (4) approximately 15% (3–4/19) of patients have either absences, atonic, or tonic seizures; (5) single patients might have peculiar and unusual phenotypes consisting of CSWS, nonconvulsive status epilepticus (NCSE) or myoclonic seizures or eyelid myoclonia, and photosensitive seizures. Of course, most patients manifest more than 1 seizure type that combined the result in unspecified EE or more rarely to known epilepsy syndromes including West, Lennox-Gastaut, and Jeavons syndromes.</p>
<p>Likewise, previously published patients, in our small series, seizures started in infancy, around 1 year of age, and were also drug resistant at onset. Yet, over time in 4 of our 6 patients (66.6%), seizure frequency attenuated and disappeared, still being under remission after a seizure-free period of 6 years. Two patients are also at present off AEDs. The reason why there is such a wide spectrum of epilepsy severity in this and in other EIEE remains a true mystery at present. Thus, further speculative discussion is better postponed until we improve our understanding about the underlying pathophysiologic mechanism and how individual genetic backgrounds influence outcomes.</p>
<p>Long-term follow-up of our 6 patients showed that following delay of milestone acquisition and despite seizure freedom, they evolved into moderate to severe impairment of cognitive functions including psychiatric symptoms and autistic traits. Overall, these findings indicate that Kv2.1 impaired function causes diffuse brain dysfunction expressing, in humans, as epilepsy and developmental or behavioral disorders. Thus, it might be more appropriate to define patients with <italic>KCNB1</italic> mutations as having developmental encephalopathy with epilepsy. An intermingled pathophysiologic relationship between the triad of seizures/ASD/ID and potassium channel genes is further supported by the identification of mutations in <italic>KCNJ10</italic>, a gene coding for the inwardly rectifying potassium channel Kir4.1, in several probands exhibiting seizures, ASD, and ID.<sup><xref ref-type="bibr" rid="R33">33</xref></sup></p>
<p>All mutations reported here were de novo and included 4 missense and 2 nonsense variants. None of the mutations appeared in allele frequency databases (table e-1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXG/A0">http://links.lww.com/NXG/A0</ext-link>), and all were predicted to be damaging by several prediction tools and ensemble scores (table e-1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXG/A0">http://links.lww.com/NXG/A0</ext-link>) and novel, with the exception of the p.Arg306Cys falling in the S4 of the voltage-sensor domain and demonstrated to be damaging by Saitsu et al.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> Patients carrying the p.Arg306Cys mutation appear to have different phenotypes. The patient we are reporting in this study has generalized epilepsy with myoclonic seizures and eyelid myoclonia, while the patient described by Saitsu et al.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> had a more severe phenotype with earlier seizure onset and heterogeneous, drug-resistant, seizures including infantile spasms, myoclonic, tonic-clonic, and focal seizures. The latter patient manifested also severe ID and macrocephaly unlike the one we are reporting, who had a normal head size and moderate ID.</p>
<p>While assessing genotype-phenotype correlations, we noted that both p.Trp370* and p.Arg583* nonsense mutations occurred in the 2 patients with remitting infantile-onset spasms and severe cognitive impairment. At present, there is a single previously reported nonsense mutation<sup><xref ref-type="bibr" rid="R14">14</xref></sup> in a patient with EE, yet detailed clinical features are not available for further correlations.</p>
<p>The remaining 2 mutations, p.Ile196Phe and the p.Thr210Met, both predicted to be damaging, are missense variants (<xref ref-type="table" rid="T1">table 1</xref>) located in the S1 and in the S1–S2 extracellular loop. The S1–S4 segments serve as the voltage-sensing module, and the voltage sensitivity of the channel is conferred by a series of highly conserved basic side chains in the S4 segment. These side chains are stabilized in a transmembrane configuration by the formation of fully solvated salt bridges with a set of highly conserved acidic side chains in S1–S3.<sup><xref ref-type="bibr" rid="R34">34</xref></sup> The p.Ile196Phe and p.Thr210Met mutations are located in the S1 conserved acidic side chains and are therefore likely to impair the structural signature of voltage-sensing motion between S1–S3 and S4 segments.<sup><xref ref-type="bibr" rid="R35">35</xref></sup></p>
<p>NGS and Sanger sequencing showed that the p.Val349Phe variant was present as mosaicism although associated with the most refractory epilepsy type in our cohort. This might correlate with the location of this mutation in the pore-forming region of the channel, thus supposedly causing a severe alteration of its function. A missense mutation located very closely, at position 347, causing severe impairment of the channel function and associated with refractory epilepsy strikingly resembling our patient's phenotype, had previously been reported.<sup><xref ref-type="bibr" rid="R8">8</xref></sup></p>
<p>Patch-clamp studies have demonstrated that some <italic>KCNB1</italic> variants cause significant alterations of Kv2.1 channel function and increased excitability of cortical neurons. Functional studies suggested different mechanisms including abolished voltage-activated gating, loss of ion selectivity,<sup><xref ref-type="bibr" rid="R11">11</xref></sup> gain of depolarizing inward cation,<sup><xref ref-type="bibr" rid="R8">8</xref></sup> defects in expression and subcellular localization,<sup><xref ref-type="bibr" rid="R8">8</xref></sup> disruption of sensitivity and cooperativity of the sensor,<sup><xref ref-type="bibr" rid="R10">10</xref></sup> and abolished endogenous Kv2.1 currents.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> The role of K<sup>+</sup> channels in the neurobiology of both epilepsy and cognitive impairment has been investigated also using animal models. Mice lacking Kv2.1 are strikingly hyperactive, defective in spatial learning, hypersensitive to convulsants, and exhibit accelerated seizure progression.<sup><xref ref-type="bibr" rid="R36">36</xref></sup> Moreover, the Kcnb1<sup>−/−</sup> mice model showed neuronal hyperexcitability and confirmed the critical role of Kv2.1 in hippocampal neuronal network homeostatic regulation.<sup><xref ref-type="bibr" rid="R36">36</xref></sup></p>
<p>Thus, <italic>KCNB1</italic>-related manifestations comprise a wide spectrum of infantile onset generalized or focal seizures whose combination leads to EIEE, including West, Lennox-Gastaut, and Jeavons syndromes. Long-term follow-up highlights that following a stormy phase, seizures cease and AEDs might be withdrawn at least in some patients. Instead, cognitive and motor functions are almost always delayed prior to seizure onset and evolve into severe, persistent impairment. Altogether, these findings suggest that <italic>KCNB1</italic> mutations are associated with diffuse brain dysfunction and that the <italic>KCNB1-</italic>related clinical picture might also be defined as a developmental “encephalopathy” with seizures. Further understanding of the underlying pathophysiology by experimental studies including animal models is required to improve treatment and prognosis of these disorders.</p>
</sec>
</body>
<back>
<sec sec-type="contributions">
<title>AUTHOR CONTRIBUTIONS</title>
<p content-type="contributions">Carla Marini, Michele Romoli, Elena Parrini, and Paolo Prontera: study design, data collection and analysis, and manuscript preparation. Francesco Mari, Cinzia Costa, Lucio Parmeggiani, Tiziana Metitieri, and Mattia Gentile: data collection and analysis and manuscript revision. Davide Mei, Elena Cellini, Simona Virdò, and Dalila De Vita: genetic study, data collection and analysis, and manuscript revision. Paolo Calabresi and Renzo Guerrini: study design, data analysis, and manuscript revision.</p>
</sec>
<sec sec-type="funding">
<title>STUDY FUNDING</title>
<p content-type="funding">This work was supported by a grant from the EU Seventh Framework Programme FP7 under the project DESIRE (grant agreement no. 602531) (to R.G.) and by the Italian Ministry of Health (grant agreement no. RF-2013-02355240) (to R.G.).</p>
</sec>
<sec sec-type="disclosure">
<title>DISCLOSURE</title>
<p content-type="disclosure">Carla Marini has received travel funding and/or speaker honoraria at VII CONGRESSO NAZIONALE SIMMESN–Firenze, December 16–18, 2015, from SOBI, Swedish Orphan Biovitrum; has served on the editorial boards of <italic>Epilepsia</italic> and <italic>Epileptic Disorders</italic>; and has received research support from the Italian Ministry of Health and Cariplo Foundation. Michele Romoli, Elena Parrini, and Cinzia Costa report no disclosures. Davide Mei has received funding for travel or speaker honoraria from BioMarin Pharmaceutical and serves on the editorial board of <italic>Epilepsia</italic>. Francesco Mari, Lucio Parmeggiani, Elena Procopio, Tiziana Metitieri, Elena Cellini, Simona Virdò, Dalila De Vita, Mattia Gentile, Paolo Prontera, and Paolo Calabresi report no disclosures. Renzo Guerrini has served on scientific advisory boards of Eisai Inc., Novartis, Zogenix, and BioMarin; has received funding for travel and/or speaker honoraria from EISAI, Novartis, UCB, and BioMarin; has served on the editorial boards of <italic>Epilepsia</italic>, <italic>Progress in Epileptic Disorders</italic>, <italic>Neuropediatrics</italic>, <italic>Journal of Child Neurology</italic>, <italic>Seizure</italic>, <italic>BMC Medical Genetics</italic>, <italic>Topics in Epilepsy</italic>, <italic>Journal of Pediatric Epilepsy</italic>, <italic>Epileptic Disorders</italic>, <italic>European Neurological Journal</italic>, <italic>Neurology</italic>, and <italic>Journal of Embryology &amp; Developmental Biology</italic>; receives/has received royalties from the publication of Epilepsy and Movements disorders (Cambridge University Press, 2002), Aicardi's Epilepsy in Children (Lippincott Williams &amp; Wilkins, 2004), Progress in Epileptic Spasms and West Syndrome (John Libbey Eurotext, 2007), Epilepsy and Migraine (John Libbey Eurotext, 2009), The Causes of Epilepsy (Cambridge University Press, 2011), Dravet syndrome (John Libbey Eurotext, 2011), and Epilepsy and epileptic seizures (Oxford University Press, 2012); and has received research support from Tuscany Region Research Department, EU and EC Programs, the Italian Ministry of Health, and the PISA Foundation. Go to <ext-link ext-link-type="uri" xlink:href="http://ng.neurology.org/lookup/doi/10.1212/NXG.0000000000000206">Neurology.org/ng</ext-link> for full disclosure forms.</p>
</sec>
<glossary>
<title>GLOSSARY</title>
<def-list>
<def-item>
<term id="G1">ACMG</term>
<def>
<p>American College of Medical Genetics and Genomics</p>
</def>
</def-item>
<def-item>
<term id="G2">AED</term>
<def>
<p>antiepileptic drug</p>
</def>
</def-item>
<def-item>
<term id="G3">ASD</term>
<def>
<p>autism spectrum disorder</p>
</def>
</def-item>
<def-item>
<term id="G4">CSWS</term>
<def>
<p>continuous spikes and waves during slow-wave sleep</p>
</def>
</def-item>
<def-item>
<term id="G5">EIEE</term>
<def>
<p>early infantile epileptic encephalopathy</p>
</def>
</def-item>
<def-item>
<term id="G6">ESP</term>
<def>
<p>Exome Sequencing Project</p>
</def>
</def-item>
<def-item>
<term id="G7">ExAC</term>
<def>
<p>Exome Aggregation Consortium</p>
</def>
</def-item>
<def-item>
<term id="G8">FS</term>
<def>
<p>febrile seizures</p>
</def>
</def-item>
<def-item>
<term id="G9">ID</term>
<def>
<p>intellectual disability</p>
</def>
</def-item>
<def-item>
<term id="G10">NGS</term>
<def>
<p>next-generation sequencing</p>
</def>
</def-item>
<def-item>
<term id="G11">TCS</term>
<def>
<p>tonic-clonic seizures</p>
</def>
</def-item>
<def-item>
<term id="G12">VPA</term>
<def>
<p>valproic acid</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>REFERENCES</title>
<ref id="R1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Fotuhi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bredt</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Cunningham</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Snyder</surname><given-names>SH</given-names></name></person-group>
<article-title>Contrasting immunohistochemical localizations in rat brain of two novel K+ channels of the Shab subfamily</article-title>. <source/>J Neurosci
<year>1993</year>;<volume>13</volume>:<fpage>1569</fpage>–<lpage>1576</lpage>.<pub-id pub-id-type="pmid">8463836</pub-id></mixed-citation>
</ref>
<ref id="R2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maletic-Savatic</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lenn</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Trimmer</surname><given-names>JS</given-names></name></person-group>
<article-title>Differential spatiotemporal expression of K+ channel polypeptides in rat hippocampal neurons developing in situ and in vitro</article-title>. <source/>J Neurosci
<year>1995</year>;<volume>15</volume>:<fpage>3840</fpage>–<lpage>3851</lpage>.<pub-id pub-id-type="pmid">7751950</pub-id></mixed-citation>
</ref>
<ref id="R3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tao-Cheng</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Zerfas</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>
<article-title>The K+ channel, Kv2.1, is apposed to astrocytic processes and is associated with inhibitory postsynaptic membranes in hippocampal and cortical principal neurons and inhibitory interneurons</article-title>. <source/>Neuroscience
<year>1998</year>;<volume>84</volume>:<fpage>37</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">9522360</pub-id></mixed-citation>
</ref>
<ref id="R4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Bean</surname><given-names>BP</given-names></name></person-group>
<article-title>Kv2 channel regulation of action potential repolarization and firing patterns in superior cervical ganglion neurons and hippocampal CA1 pyramidal neurons</article-title>. <source/>J Neurosci
<year>2014</year>;<volume>34</volume>:<fpage>4991</fpage>–<lpage>5002</lpage>.<pub-id pub-id-type="pmid">24695716</pub-id></mixed-citation>
</ref>
<ref id="R5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Misonou</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Mohapatra</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>EW</given-names></name>, <etal>et al</etal></person-group>
<article-title>Regulation of ion channel localization and phosphorylation by neuronal activity</article-title>. <source/>Nat Neurosci
<year>2004</year>;<volume>7</volume>:<fpage>711</fpage>–<lpage>718</lpage>.<pub-id pub-id-type="pmid">15195093</pub-id></mixed-citation>
</ref>
<ref id="R6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Misonou</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>X</given-names></name></person-group>
<article-title>Dynamic regulation of the Kv2.1 voltage-gated potassium channel during brain ischemia through neuroglial interaction</article-title>. <source/>J Neurosci
<year>2008</year>;<volume>28</volume>:<fpage>8529</fpage>–<lpage>8538</lpage>.<pub-id pub-id-type="pmid">18716211</pub-id></mixed-citation>
</ref>
<ref id="R7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>PD</given-names></name>, <name name-style="western"><surname>Loftus</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Tamkun</surname><given-names>MM</given-names></name></person-group>
<article-title>Regulation of Kv2.1 K(+) conductance by cell surface channel density</article-title>. <source/>J Neurosci
<year>2013</year>;<volume>3</volume>:<fpage>1259</fpage>–<lpage>1270</lpage>.</mixed-citation>
</ref>
<ref id="R8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torkamani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bersell</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Jorge</surname><given-names>BS</given-names></name>, <etal>et al</etal></person-group>
<article-title>De novo <italic>KCNB1</italic> mutations in epileptic encephalopathy</article-title>. <source/>Ann Neurol
<year>2014</year>;<volume>76</volume>:<fpage>529</fpage>–<lpage>540</lpage>.<pub-id pub-id-type="pmid">25164438</pub-id></mixed-citation>
</ref>
<ref id="R9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Vernon</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>
<article-title>Clinical whole exome sequencing in child neurology practice</article-title>. <source/>Ann Neurol
<year>2014</year>;<volume>76</volume>:<fpage>473</fpage>–<lpage>483</lpage>.<pub-id pub-id-type="pmid">25131622</pub-id></mixed-citation>
</ref>
<ref id="R10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saitsu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Akita</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tohyama</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>De novo <italic>KCNB1</italic> mutations in infantile epilepsy inhibit repetitive neuronal firing</article-title>. <source/>Sci Rep
<year>2015</year>;<volume>5</volume>:<fpage>15199</fpage>.<pub-id pub-id-type="pmid">26477325</pub-id></mixed-citation>
</ref>
<ref id="R11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thiffault</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Speca</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Austin</surname><given-names>DC</given-names></name>, <etal>et al</etal></person-group>
<article-title>A novel epileptic encephalopathy mutation in <italic>KCNB1</italic> disrupts Kv2.1 ion selectivity, expression, and localization</article-title>. <source/>J Gen Physiol
<year>2015</year>;<volume>146</volume>:<fpage>399</fpage>–<lpage>410</lpage>.<pub-id pub-id-type="pmid">26503721</pub-id></mixed-citation>
</ref>
<ref id="R12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Conroy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shahwan</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Unexplained early onset epileptic encephalopathy: exome screening and phenotype expansion</article-title>. <source/>Epilepsia
<year>2016</year>;<volume>57</volume>:<fpage>e12</fpage>–<lpage>e17</lpage>.<pub-id pub-id-type="pmid">26648591</pub-id></mixed-citation>
</ref>
<ref id="R13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Latypova</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Matsumoto</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Vinceslas-Muller</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Novel <italic>KCNB1</italic> mutation associated with non-syndromic intellectual disability</article-title>. <source/>J Hum Genet
<year>2017</year>;<volume>62</volume>:<fpage>569</fpage>–<lpage>573</lpage>.<pub-id pub-id-type="pmid">27928161</pub-id></mixed-citation>
</ref>
<ref id="R14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Kovel</surname><given-names>CGF</given-names></name>, <name name-style="western"><surname>Brilstra</surname><given-names>EH</given-names></name>, <name name-style="western"><surname>van Kempen</surname><given-names>MJA</given-names></name>, <etal>et al</etal></person-group>
<article-title>Targeted sequencing of 351 candidate genes for epileptic encephalopathy in a large cohort of patients</article-title>. <source/>Mol Genet Genomic Med
<year>2016</year>;<volume>4</volume>:<fpage>568</fpage>–<lpage>580</lpage>.<pub-id pub-id-type="pmid">27652284</pub-id></mixed-citation>
</ref>
<ref id="R15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>A novel mutation in <italic>KCNB1</italic> gene in a child with neuropsychiatric comorbidities with both intellectual disability and epilepsy and review of literature</article-title>. <source/>Zhonghua Er Ke Za Zhi
<year>2017</year>;<volume>55</volume>:<fpage>115</fpage>–<lpage>119</lpage>.<pub-id pub-id-type="pmid">28173649</pub-id></mixed-citation>
</ref>
<ref id="R16">
<label>16.</label>
<mixed-citation publication-type="journal"><collab>Commission on Classification and Terminology of the International League Against Epilepsy</collab>. <article-title>Proposal for revised classification of epilepsies and epileptic syndromes</article-title>. <source/>Epilepsia
<year>1989</year>;<volume>30</volume>:<fpage>389</fpage>–<lpage>399</lpage>.<pub-id pub-id-type="pmid">2502382</pub-id></mixed-citation>
</ref>
<ref id="R17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berg</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Berkovic</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Brodie</surname><given-names>MJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009</article-title>. <source/>Epilepsia
<year>2010</year>;<volume>51</volume>:<fpage>676</fpage>–<lpage>685</lpage>.<pub-id pub-id-type="pmid">20196795</pub-id></mixed-citation>
</ref>
<ref id="R18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parrini</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Marini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mei</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Diagnostic targeted resequencing in 349 patients with drug-resistant pediatric epilepsies identifies causative mutations in 30 different genes</article-title>. <source/>Hum Mutat
<year>2017</year>;<volume>38</volume>:<fpage>216</fpage>–<lpage>225</lpage>.<pub-id pub-id-type="pmid">27864847</pub-id></mixed-citation>
</ref>
<ref id="R19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>K</given-names></name></person-group>
<article-title>Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR</article-title>. <source/>Nat Protoc
<year>2015</year>;<volume>10</volume>:<fpage>1556</fpage>–<lpage>1566</lpage>.<pub-id pub-id-type="pmid">26379229</pub-id></mixed-citation>
</ref>
<ref id="R20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richards</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Aziz</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bale</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>. <source/>Genet Med
<year>2015</year>;<volume>17</volume>:<fpage>405</fpage>–<lpage>424</lpage>.<pub-id pub-id-type="pmid">25741868</pub-id></mixed-citation>
</ref>
<ref id="R21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caraballo</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Fontana</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Darra</surname><given-names>F</given-names></name>, <etal>et al</etal></person-group>
<article-title>A study of 63 cases with eyelid myoclonia with or without absences: type of seizure or an epileptic syndrome?</article-title>
<source/>Seizure
<year>2009</year>;<volume>18</volume>:<fpage>440</fpage>–<lpage>445</lpage>.<pub-id pub-id-type="pmid">19419888</pub-id></mixed-citation>
</ref>
<ref id="R22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biervert</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Schroeder</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Kubisch</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>A potassium channel mutation in neonatal human epilepsy</article-title>. <source/>Science
<year>1998</year>;<volume>279</volume>:<fpage>403</fpage>–<lpage>406</lpage>.<pub-id pub-id-type="pmid">9430594</pub-id></mixed-citation>
</ref>
<ref id="R23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charlier</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Ryan</surname><given-names>SG</given-names></name>, <etal>et al</etal></person-group>
<article-title>A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family</article-title>. <source/>Nat Genet
<year>1998</year>;<volume>18</volume>:<fpage>53</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">9425900</pub-id></mixed-citation>
</ref>
<ref id="R24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Charlier</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Stauffer</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>A novel potassium channel gene KCNQ2 is mutated in an inherited epilepsy of newborns</article-title>. <source/>Nat Genet
<year>1998</year>;<volume>18</volume>:<fpage>25</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="pmid">9425895</pub-id></mixed-citation>
</ref>
<ref id="R25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benarroch</surname><given-names>EE</given-names></name></person-group>
<article-title>Potassium channels: brief overview and implications in epilepsy</article-title>. <source/>Neurology
<year>2009</year>;<volume>72</volume>:<fpage>664</fpage>–<lpage>669</lpage>.<pub-id pub-id-type="pmid">19221301</pub-id></mixed-citation>
</ref>
<ref id="R26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muona</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Berkovic</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Dibbens</surname><given-names>LM</given-names></name>, <etal>et al</etal></person-group>
<article-title>A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy</article-title>. <source/>Nat Genet
<year>2015</year>;<volume>47</volume>:<fpage>39</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">25401298</pub-id></mixed-citation>
</ref>
<ref id="R27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simons</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Rash</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Crawford</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>Mutations in the voltage-gated potassium channel gene KCNH1 cause Temple-Baraitser syndrome and epilepsy</article-title>. <source/>Nat Genet
<year>2015</year>;<volume>47</volume>:<fpage>73</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="pmid">25420144</pub-id></mixed-citation>
</ref>
<ref id="R28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Bautista</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>
<article-title>Calcium-sensitive potassium channelopathy in human epilepsy and paroxysmal movement disorder</article-title>. <source/>Nat Genet
<year>2005</year>;<volume>37</volume>:<fpage>733</fpage>–<lpage>778</lpage>.<pub-id pub-id-type="pmid">15937479</pub-id></mixed-citation>
</ref>
<ref id="R29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nava</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Dalle</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Rastetter</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>De novo mutations in HCN1 cause early infantile epileptic encephalopathy</article-title>. <source/>Nat Genet
<year>2014</year>;<volume>46</volume>:<fpage>640</fpage>–<lpage>645</lpage>.<pub-id pub-id-type="pmid">24747641</pub-id></mixed-citation>
</ref>
<ref id="R30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barcia</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Fleming</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Deligniere</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy</article-title>. <source/>Nat Genet
<year>2012</year>;<volume>44</volume>:<fpage>1255</fpage>–<lpage>1259</lpage>.<pub-id pub-id-type="pmid">23086397</pub-id></mixed-citation>
</ref>
<ref id="R31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Syrbe</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hedrich</surname><given-names>UB</given-names></name>, <name name-style="western"><surname>Riesch</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>
<article-title>De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy</article-title>. <source/>Nat Genet
<year>2015</year>;<volume>47</volume>:<fpage>393</fpage>–<lpage>399</lpage>.<pub-id pub-id-type="pmid">25751627</pub-id></mixed-citation>
</ref>
<ref id="R32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eunson</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Rea</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zuberi</surname><given-names>SM</given-names></name>, <etal>et al</etal></person-group>
<article-title>Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability</article-title>. <source/>Ann Neurol
<year>2000</year>;<volume>48</volume>:<fpage>647</fpage>–<lpage>656</lpage>.<pub-id pub-id-type="pmid">11026449</pub-id></mixed-citation>
</ref>
<ref id="R33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sicca</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Imbrici</surname><given-names>P</given-names></name>, <name name-style="western"><surname>D'Adamo</surname><given-names>MC</given-names></name>, <etal>et al</etal></person-group>
<article-title>Autism with seizures and intellectual disability: possible causative role of gain-of-function of the inwardly-rectifying K+ channel Kir4.1</article-title>. <source/>Neurobiol Dis
<year>2011</year>;<volume>43</volume>:<fpage>239</fpage>–<lpage>247</lpage>.<pub-id pub-id-type="pmid">21458570</pub-id></mixed-citation>
</ref>
<ref id="R34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Freites</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Tombola</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Tobias</surname><given-names>DJ</given-names></name></person-group>
<article-title>Atomistic modeling of ion conduction through the voltage-sensing domain of the Shaker K<sup>+</sup> ion channel</article-title>. <source/>J Phys Chem B
<year>2017</year>;<volume>121</volume>:<fpage>3804</fpage>–<lpage>3812</lpage>.<pub-id pub-id-type="pmid">28074656</pub-id></mixed-citation>
</ref>
<ref id="R35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freites</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Tobias</surname><given-names>DJ</given-names></name></person-group>
<article-title>Voltage sensing in membranes: from macroscopic currents to molecular motions</article-title>. <source/>J Membr Biol
<year>2015</year>;<volume>248</volume>:<fpage>419</fpage>–<lpage>430</lpage>.<pub-id pub-id-type="pmid">25972106</pub-id></mixed-citation>
</ref>
<ref id="R36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Speca</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Ogata</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Mandikian</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Deletion of the Kv2.1 delayed rectifier potassium channel leads to neuronal and behavioral hyperexcitability</article-title>. <source/>Genes Brain Behav
<year>2014</year>;<volume>13</volume>:<fpage>394</fpage>–<lpage>408</lpage>.<pub-id pub-id-type="pmid">24494598</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>